WC
SGMO

Wexford Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Wexford Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-45,450
Closed -$24.7K – 277
2023
Q4 		$24.7K Buy
+45,450
New +$21K 0.01% 175
2018
Q3 		– Sell
-127,800
Closed -$1.81M – 171
2018
Q2 		$1.81M Buy
+127,800
New +$2.12M 0.12% 75
2016
Q3 		– Sell
-49,432
Closed -$286K – 181
2016
Q2 		$286K Hold
49,432
– – 0.05% 109
2016
Q1 		$299K Buy
+49,432
New +$297K 0.06% 95
2015
Q4 		– Sell
-67,000
Closed -$378K – 87
2015
Q3 		$378K Buy
+67,000
New +$552K 0.07% 77

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wexford Capital's SGMO Position: Q1 2024 in Review

Wexford Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2024, closing a stake of 45,450 shares — an estimated $24.7K sold.

Wexford Capital first reported a position in SGMO in Q3 2015 and held it in 5 quarters. The position peaked at $1.81M in Q2 2018. 131 funds tracked by Wall St. Rank hold SGMO as of Q1 2024.

  • Wexford Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2024 after selling out during the quarter.
  • Wexford Capital sold 45,450 SANGAMO THERAPEUTICS INC shares in Q1 2024, an estimated $24.7K.
  • Wexford Capital first reported a position in SANGAMO THERAPEUTICS INC in Q3 2015 and held it in 5 quarters.
  • Wexford Capital's SANGAMO THERAPEUTICS INC position peaked at $1.81M in Q2 2018.
  • 131 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.